Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy;Medida de função motora, corticoterapia e pacientes com distrofia muscular de Duchenne

Arquivos de Neuro-Psiquiatria

Volumn 70, Issue 3, 2012, Pages 191-195

  da Silva, Elaine C ^a   Machado, Darlene L ^a   Resende, Maria B D ^a   Silva, Renata F ^a   Zanoteli, Edmar ^b   Reed, Umbertina C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Neuromuscular Section   (Brazil)

Author keywords

Duchenne; Motor function measure; Muscular dystrophy; Neuromuscular disease

Indexed keywords

DEFLAZACORT; PREDNISOLONE;

ADULT; AMBULATORY CARE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DUCHENNE MUSCULAR DYSTROPHY; EVALUATION; FEMALE; FOLLOW UP; GROSS MOTOR FUNCTION MEASURE; HUMAN; MALE; MOTOR PERFORMANCE; NEUROMUSCULAR DISEASE; PREDICTION; SCORING SYSTEM; STANDING; STEROID THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; WALKING SPEED;

EID: 84858130484     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/s0004-282x2012000300007     Document Type: Article

References (27)

1. Wagner KR. Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics 2008;5:583-591.
2. Fenichel GM, Florence JM, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-1877.
3. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long term effect. Am J Phys Med Reabil 2005;84:843-850.
4. Bushby K, Finkel R, Birnkrant D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
5. Allsop KG, Ziter FA. Loss of strengh and functional decline in Duchennés dystrophy. Arch Neurol 1981;38:406-411.
6. Scott OM, Hyde AS, Goddard C, Dubowitz V. Quantification of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve 1982;5:291-301.
7. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation I Duchenne dystrophy: 2. determination of the "power" of therapeutics trials based on the natural history. Muscle Nerve 1983;6:91-103.
8. Scott E, Mawson SJ. Measurement in Duchenne muscular dystrophy: considerations in the development of a neuromuscular assesment tool. Dev Med Child Neurol 2006;48:540-544.
9. Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the 124th ENMC international workshop treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 2004;14:526-534.
10. st July 2007, Naarden, The Netherlands; conjoint institute of myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord 2008;18:894-903.
11. Parreira SL, Resende MB, Peduto MDC, Marie SKN, Carvalho MS, Reed UC. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arq Neuropsiquiatr 2007;65:245-250.
12. Parreira SL, Resende MB, Zanoteli E, Carvalho MS, Marie SK, Reed UC. Comparison of motor strength and function in patients with Duchenne muscular dystrophy with or without steroid therapy. Arq Neuropsiquiatr 2010;68:683-688.
13. Bèrard C, Payan C, Hodgkinson I, Fermanian J, The MFM Collaborative Study Group. A motor functional measure scale for neuromuscular disease. Construction and validation study. Neuromuscul Disord 2005;15:463-470.
14. Iwabe C, Miranda-Pfeilsticker BH, Nucci AM. Medida da função motora: versão da escala para o português e estudo de confiabilidade. Rev Bras Fisioter São Carlos 2008;12:417-424.
15. Connolly A, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002;12:917-925.
16. Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child 2008;93:986-990.
17. Houde S, Filiatrault M, Fournier A, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008;38:200-206.
18. Biggar WD, Harris VA, Eliasoph L, Alman B. Long- term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
19. Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long term corticosteroid treatment implications for management. J Child Neurol 2010;25:1116-1129.
20. th October 2006, Naarden, The Netherlands. Neuromuscul Disord 2007;17:423-428.
21. Nair KPS, Vasanth A, Gourie DM, et al. Disabilities in children with Duchenne muscular dystrophy: a profile. J Rehabil Med 2001;33:147-149.
22. Vuillerot C, Girardot F, Payan C, et al. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the motor function measure. Dev Med Child Neurol 2010;52:60-65.
23. Benaïn C, Sacconi S, Fournier-Mehouas M, Tanant V, Desnuelle C. Analyse de validité de la mesure de la function motrice (MFM) en pratique de consultation adulte d́un centre de référenc pour maladies neuromusculaires. Revue Neurol (Paris) 2010;166:49-53.
24. Mc Donald CM, Abresh RT, Carter GT, et al. Profiles of neuromuscular diseases. Am J Phys Med Rehabilit 1995;74:70-92.
25. Steffensen B, Hyde S, Lyager S, Mattsson E. Validity of the EK scale: a functional assessment of non- ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Resp Inte 2001;6:119-134.
26. Martinez JAB, Brunherotti MA, Assis MR, Sobreira CFR. Validação da escala motora funcional EK para a língua portuguesa. Rev Assoc Med Bras 2006;52:347-351.
27. Bèrard C, Payan C, Fermanian J, Girardot F, Groupe d'Etude MFM. La mesure de fonction motrice, outil d'évaluation clinique des maladies neuromusculaires. Etude de validation. Rev Neurol (Paris) 2006;162:485-493.